We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
- Authors
Wilkinson, Scott; Sowalsky, Adam G
- Abstract
The article discusses the use of neoadjuvant chemohormonal therapy in the treatment of prostate cancer. Neoadjuvant therapy aims to intensify radical local therapy, such as prostatectomy, with presurgical systemic therapy to target micrometastatic tumor subclones. The study examines the molecular features of surgical samples after neoadjuvant therapy to identify factors associated with recurrence-free survival. The findings suggest that patients receiving neoadjuvant therapy have lower mutant allele sequencing-based tumor fractions and that the presence of these fractions is associated with PSA progression and any-event progression. The study also explores the presence of TP53 and SPOP point mutations and gene expression patterns in the neoadjuvant and prostatectomy arms. While neoadjuvant therapy may prolong event-free survival, it does not seem to influence resistance to future therapies. The study provides valuable insights into the biology of drug responses and mechanisms of resistance in prostate cancer.
- Subjects
PROSTATE cancer; NEOADJUVANT chemotherapy; BIOLOGY; DISEASE risk factors; CIRCULATING tumor DNA; ANDROGEN deprivation therapy
- Publication
JNCI: Journal of the National Cancer Institute, 2024, Vol 116, Issue 1, p12
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djad192